In a packed programme, the EMA's human medicines committee recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral formulation of GLP-1 agonist Wegovy ...
An unsolicited bid by private equity group CVC to take control of Italian pharma company Recordati looks likely to come off, ...
Biogen and Denali have now confirmed that the results show BIIB122 (also known as DNL151) did not slow the progression of ...
A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...
DPP1 inhibitor Brinsupri (brensocatib), given as a once-daily oral tablet, became the first therapy approved by the FDA for ...
Bayer has filed to modify the label for its chronic kidney disease (CKD) Kerendia to include people with type 1 diabetes, ...
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include ...
The 42-subject pilot study compared three weeks of treatment with Remepy's lead product candidate Hybridopa – which consists ...
The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola that is causing ...
The phase 3 trial was evaluating two doses of anti-LAG-3 antibody fianlimab in combination with PD-1 inhibitor Libtayo ...
New CDER director Richard Pazdur, who will retain his role at the FDA's Oncology Center of Excellence while a successor is sought. After a period of chaos and instability among the leadership of the ...
UK-based GHO and CBC Group of Singapore – have announced a merger to create a massive player in the category with $21 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results